Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

David Spigel; Robert Jotte; John Nemunaitis; Merrill Shum; Jeffrey Schneider; Jerome Goldschmidt; Jennifer Eisenstein; David Berz; Lasika Seneviratne; Matei Socoteanu; Viralkumar Bhanderi; Kartik Konduri; Meng Xia; Hong Wang; Rebecca R. Hozak; Ivelina Gueorguieva; David Ferry; Leena Gandhi; Bo H. Chao; Igor Rybkin

doi:10.1016/J.JTHO.2020.10.001

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

David Spigel
, Robert Jotte
, John Nemunaitis
, Merrill Shum
, Jeffrey Schneider
, Jerome Goldschmidt
, Jennifer Eisenstein
, David Berz
, Lasika Seneviratne
, Matei Socoteanu
, Viralkumar Bhanderi
, Kartik Konduri
, Meng Xia
, Hong Wang
, Rebecca R. Hozak
, Ivelina Gueorguieva
, David Ferry
, Leena Gandhi
, Bo H. Chao
, Igor Rybkin

Sarah Cannon Research Institute
U.S. Oncology Research, Houston, Texas
University of Toledo
The Oncology Institute of Hope and Innovation, Whittier, California
New York University
Oncology and Hematology Association of SW Virginia, Blacksburg, Virginia
Colorado Permanente Medical Group/Kaiser Lafayette, Denver, Colorado
Beverly Hills Cancer Center, Beverly Hills, California
Los Angeles Hematology Oncology Medical Group, Los Angeles, California
Texas Oncology
Florida Cancer Specialist, Tallahassee, Florida
Eli Lilly and Company
Ford Motor Company

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Thoracic Oncology
Volume	16
Issue number	2
DOIs	https://doi.org/10.1016/J.JTHO.2020.10.001
State	Published - Feb 1 2021
Externally published	Yes

Disciplines

Medicine and Health Sciences
Gastroenterology
Internal Medicine

Access to Document

10.1016/J.JTHO.2020.10.001License: Unspecified

Cite this

Spigel, D., Jotte, R., Nemunaitis, J., Shum, M., Schneider, J., Goldschmidt, J., Eisenstein, J., Berz, D., Seneviratne, L., Socoteanu, M., Bhanderi, V., Konduri, K., Xia, M., Wang, H., Hozak, R. R., Gueorguieva, I., Ferry, D., Gandhi, L., Chao, B. H., & Rybkin, I. (2021). Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2). Journal of Thoracic Oncology, 16(2). https://doi.org/10.1016/J.JTHO.2020.10.001

Spigel, D, Jotte, R, Nemunaitis, J, Shum, M, Schneider, J, Goldschmidt, J, Eisenstein, J, Berz, D, Seneviratne, L, Socoteanu, M, Bhanderi, V, Konduri, K, Xia, M, Wang, H, Hozak, RR, Gueorguieva, I, Ferry, D, Gandhi, L, Chao, BH & Rybkin, I 2021, 'Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)', Journal of Thoracic Oncology, vol. 16, no. 2. https://doi.org/10.1016/J.JTHO.2020.10.001

@article{363f7340ca844df7b08265918b43c66a,

title = "Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)",

author = "David Spigel and Robert Jotte and John Nemunaitis and Merrill Shum and Jeffrey Schneider and Jerome Goldschmidt and Jennifer Eisenstein and David Berz and Lasika Seneviratne and Matei Socoteanu and Viralkumar Bhanderi and Kartik Konduri and Meng Xia and Hong Wang and Hozak, \{Rebecca R.\} and Ivelina Gueorguieva and David Ferry and Leena Gandhi and Chao, \{Bo H.\} and Igor Rybkin",

note = "Introduction Checkpoint inhibitors (CPIs) have been approved to treat metastatic NSCLC. Pegilodecakin + CPI suggested promising efficacy in phase 1 IVY, providing rationale for randomized phase 2 trials CYPRESS 1 and CYPRESS 2. Methods CYPRESS 1 (N = 101) and CYPRESS 2 (N = 52) included Eastern Cooperative Oncology Group performance status of 0 to 1 and first-line/second-line metastatic NSCLC, respectively, without known EGFR/ALK mutations.",

year = "2021",

month = feb,

day = "1",

doi = "10.1016/J.JTHO.2020.10.001",

language = "American English",

volume = "16",

journal = "Journal of Thoracic Oncology",

number = "2",

}

TY - JOUR

T1 - Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

AU - Spigel, David

AU - Jotte, Robert

AU - Nemunaitis, John

AU - Shum, Merrill

AU - Schneider, Jeffrey

AU - Goldschmidt, Jerome

AU - Eisenstein, Jennifer

AU - Berz, David

AU - Seneviratne, Lasika

AU - Socoteanu, Matei

AU - Bhanderi, Viralkumar

AU - Konduri, Kartik

AU - Xia, Meng

AU - Wang, Hong

AU - Hozak, Rebecca R.

AU - Gueorguieva, Ivelina

AU - Ferry, David

AU - Gandhi, Leena

AU - Chao, Bo H.

AU - Rybkin, Igor

N1 - Introduction Checkpoint inhibitors (CPIs) have been approved to treat metastatic NSCLC. Pegilodecakin + CPI suggested promising efficacy in phase 1 IVY, providing rationale for randomized phase 2 trials CYPRESS 1 and CYPRESS 2. Methods CYPRESS 1 (N = 101) and CYPRESS 2 (N = 52) included Eastern Cooperative Oncology Group performance status of 0 to 1 and first-line/second-line metastatic NSCLC, respectively, without known EGFR/ALK mutations.

PY - 2021/2/1

Y1 - 2021/2/1

UR - https://europepmc.org/article/MED/33166722

U2 - 10.1016/J.JTHO.2020.10.001

DO - 10.1016/J.JTHO.2020.10.001

M3 - Article

VL - 16

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 2

ER -

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

Disciplines

Access to Document

Other files and links

Cite this